Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-493/ABT-530 in Adults With Chronic HCV and Compensated Cirrhosis
NCT02642432Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2015
- Primary completion
- Oct 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of glecaprevir, pibrentasvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Dec 2015; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02642432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02642432.